Movement Alert｜10x Genomics, Inc. Rises 5.09% in Regular Trading, Q2 Earnings Beat and Raised Full-Year Guidance Continue to Lift Shares

Market Focus08-10 21:50

On August 10, 10x Genomics, Inc. rose 5.09% in regular trading, trading at $53.98 per share, with turnover of $16.73 million. The stock continues to rally following the release of better-than-expected second quarter results and an upward revision to full-year revenue guidance.

The company reported Q2 EPS loss of $0.14, significantly beating the analyst consensus estimate of a $0.24 loss by 41.67%. Revenue came in at $151.0 million, surpassing the $146.7 million estimate. Additionally, management raised full-year revenue guidance to $610 million-$630 million, up from the prior range of $600 million-$625 million, and above analyst expectations of $613.7 million. While revenue declined 12.7% year-over-year and the company swung to a loss from EPS of $0.28 in the prior-year period, the magnitude of the earnings beat combined with the guidance raise has sustained positive market sentiment and extended the stock's rebound trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185984582?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185984582","market":"hk","top_or_hot":-1,"title":"Movement Alert｜10x Genomics, Inc. Rises 5.09% in Regular Trading, Q2 Earnings Beat and Raised Full-Year Guidance Continue to Lift Shares","media":"Market Focus","content":"<p><p>On August 10, 10x Genomics, Inc. rose 5.09% in regular trading, trading at $53.98 per share, with turnover of $16.73 million. The stock continues to rally following the release of better-than-expected second quarter results and an upward revision to full-year revenue guidance.</p><p>The company reported Q2 EPS loss of $0.14, significantly beating the analyst consensus estimate of a $0.24 loss by 41.67%. Revenue came in at $151.0 million, surpassing the $146.7 million estimate. Additionally, management raised full-year revenue guidance to $610 million-$630 million, up from the prior range of $600 million-$625 million, and above analyst expectations of $613.7 million. While revenue declined 12.7% year-over-year and the company swung to a loss from EPS of $0.28 in the prior-year period, the magnitude of the earnings beat combined with the guidance raise has sustained positive market sentiment and extended the stock's rebound trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜10x Genomics, Inc. Rises 5.09% in Regular Trading, Q2 Earnings Beat and Raised Full-Year Guidance Continue to Lift Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜10x Genomics, Inc. Rises 5.09% in Regular Trading, Q2 Earnings Beat and Raised Full-Year Guidance Continue to Lift Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, 10x Genomics, Inc. rose 5.09% in regular trading, trading at $53.98 per share, with turnover of $16.73 million. The stock continues to rally following the release of better-than-expected second quarter results and an upward revision to full-year revenue guidance.</p><p>The company reported Q2 EPS loss of $0.14, significantly beating the analyst consensus estimate of a $0.24 loss by 41.67%. Revenue came in at $151.0 million, surpassing the $146.7 million estimate. Additionally, management raised full-year revenue guidance to $610 million-$630 million, up from the prior range of $600 million-$625 million, and above analyst expectations of $613.7 million. While revenue declined 12.7% year-over-year and the company swung to a loss from EPS of $0.28 in the prior-year period, the magnitude of the earnings beat combined with the guidance raise has sustained positive market sentiment and extended the stock's rebound trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1185984582","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185984582","pubTimestamp":1786369827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, 10x Genomics, Inc. rose 5.09% in regular trading, trading at $53.98 per share, with turnover of $16.73 million. The stock continues to rally following the release of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"走势警报|10x Genomics, Inc. 常规交易中上涨 5.09%，第二季度盈利超出预期并上调全年指引继续提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"On August 10, 10x Genomics, Inc. rose 5.09% in regular trading, trading at $53.98 per share, with turnover of $16.73 million. The stock continues to rally following the release of better-than-expected second quarter results and an upward revision to full-year revenue guidance.The company reported Q2 EPS loss of $0.14, significantly beating the analyst consensus estimate of a $0.24 loss by 41.67%. Revenue came in at $151.0 million, surpassing the $146.7 million estimate. Additionally, management raised full-year revenue guidance to $610 million-$630 million, up from the prior range of $600 million-$625 million, and above analyst expectations of $613.7 million. While revenue declined 12.7% year-over-year and the company swung to a loss from EPS of $0.28 in the prior-year period, the magnitude of the earnings beat combined with the guidance raise has sustained positive market sentiment and extended the stock's rebound trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185984582","isCrawlerRequest":true}